Carlyle Group Files 13D Amendment for Soleno Therapeutics
Ticker: SLNO · Form: SC 13D/A · Filed: Sep 10, 2024 · CIK: 1484565
| Field | Detail |
|---|---|
| Company | Soleno Therapeutics Inc (SLNO) |
| Form Type | SC 13D/A |
| Filed Date | Sep 10, 2024 |
| Risk Level | medium |
| Pages | 10 |
| Reading Time | 12 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, investment-firm
Related Tickers: SNLO
TL;DR
Carlyle Group updated its Soleno Therapeutics stake on 9/10/24. Watch for potential moves.
AI Summary
Carlyle Group Inc. and its affiliates, including Abingworth Bioventures VII LP, have filed an amendment to their Schedule 13D, reporting a change in beneficial ownership of Soleno Therapeutics Inc. as of September 10, 2024. The filing details the group members involved in this reporting entity.
Why It Matters
This filing indicates a significant change in the ownership structure of Soleno Therapeutics, potentially impacting its stock and strategic direction.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership by major investment firms can signal shifts in strategy or potential future actions that could affect the company's stock price.
Key Players & Entities
- Carlyle Group Inc. (company) — Filing entity
- Abingworth Bioventures VII LP (company) — Group member of filing entity
- Soleno Therapeutics Inc. (company) — Subject company
- 20240910 (date) — Date of change in beneficial ownership
FAQ
What specific change in beneficial ownership is reported by Carlyle Group Inc. for Soleno Therapeutics?
The filing is an amendment to a Schedule 13D, indicating a change in beneficial ownership, but the exact percentage or number of shares acquired or disposed of is not detailed in the provided text.
Who are the key group members associated with Carlyle Group Inc. in this filing?
Key group members include Abingworth Bioventures VII LP, Abingworth LLP, Carlyle Genesis UK LLC, Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., Carlyle Investment Management L.L.C., CG Subsidiary Holdings L.L.C., and TC Group, L.L.C.
What is the subject company's Central Index Key (CIK)?
The CIK for Soleno Therapeutics Inc. is 0001484565.
When was the former company name of Soleno Therapeutics Inc. changed?
Soleno Therapeutics Inc. was formerly known as Capnia, Inc., and the date of the name change was February 19, 2010.
What is the business address and phone number for Soleno Therapeutics Inc.?
The business address is 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065, and the business phone number is 650-213-8444.
Filing Stats: 2,971 words · 12 min read · ~10 pages · Grade level 10.7 · Accepted 2024-09-10 18:30:26
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
Filing Documents
- formsc13da.htm (SC 13D/A) — 291KB
- ex5.htm (EX-5) — 56KB
- ex5_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-035677.txt ( ) — 354KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : September 10, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures VII LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory